ALKERMES | ALKS - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
ALKERMES USD 338.34M 72.51M 2025-12
Amgen USD 6.48B 307M 2025-09
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Gilead Sciences USD 6.31B 106M 2025-12
Heron Therapeutics USD 29.47M 3.17M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
J&J USD 17.24B 642M 2026-03
Merck USD 13.42B 431M 2025-09
Minerva Neurosciences -4.27M 26.79M 2024-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Otsuka Holdings JPY 457.41B 28.26B 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12